We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of epirubicin combined with docetaxel on inflammatory factors, cytokines, tumor markers, clinical efficacy and adverse reactions in patients with cervical cancer after surgery.
- Authors
Rong Lu; Qianqian Feng; Jian Yang; Yan Ma
- Abstract
To investigate the clinical efficacy of epirubicin combined with docetaxel in postoperative patients with cervical cancer. A total of 124 postoperative cervical cancer patients were randomly allocated into two groups: the control group (n = 62) and the experimental group (n = 62), using a random number table. Patients in both groups underwent extensive hysterectomy, pelvic nerve-sparing lymphadenectomy, and other surgical interventions as deemed necessary. Postoperatively, the control group received intravenous epirubicin, while the experimental group received intravenous docetaxel in addition to epirubicin. After 3 courses of treatment, the serum levels of interleukin-2 (IL-2), IL-6, IL-4 and interferon (IFN-) in the experimental group were lower than that in the control group. The levels of IL-2/IL-6, IFN-/IL-4, IL-2/IL-4 and IFN-/IL-6 were lower than that in the control group. The serum levels of carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1) and squamous cell carcinoma antigen (SCC-Ag) were lower than that in the control group. The disease control rate was 74.19% (46/62), higher than 56.45% (35/62) in the control group. The incidence of adverse reactions was 6.45% (4/62), lower than 19.35% (12/62) in the control group. The combination of epirubicin and docetaxel demonstrates efficacy in the treatment of postoperative cervical cancer.
- Subjects
CERVICAL cancer treatment; EPIRUBICIN; DOCETAXEL; INFLAMMATION; CYTOKINES
- Publication
European Journal of Gynaecological Oncology, 2024, Vol 45, Issue 3, p160
- ISSN
0392-2936
- Publication type
Article
- DOI
10.22514/ejgo.2024.059